Crescent BIOPHARMA, Inc. (CBIO) intrinsic value & 10-year financials
Crescent BIOPHARMA, Inc. (CBIO) has no Graham intrinsic value right now because the formula needs positive earnings. Over the last 10 fiscal years revenue grew 103.0% a year to $10.8M, with an average return on invested capital of 699.8%.
- Graham intrinsic value
- —
- Share price (Oct 17, 2026)
- $11.84
- Market cap
- $763.4M
- Revenue (FY2025)
- $10.8M
- Revenue growth (10-yr CAGR)
- 103.0%
- ROIC (10-yr avg)
- 699.8%
- Free cash flow (FY2025)
- -$72.5M
CBIO 10-year financial history
| Fiscal year | Revenue | Net income | EPS (diluted) | Free cash flow | Operating margin | ROIC |
|---|---|---|---|---|---|---|
| FY2025 | $10.8M | -$153.9M | — | -$72.5M | -1407.5% | -1321.2% |
| FY2024 | — | -$37.9M | -$0.59 | -$31.1M | — | -263.4% |
| FY2023 | $10.0K | -$36.9M | -$0.58 | -$34.9M | -392752.9% | 1114.3% |
| FY2022 | $75.0K | -$46.7M | -$0.89 | -$46.5M | -63204.4% | 603.8% |
| FY2021 | $1.2M | -$63.4M | -$1.23 | -$57.5M | -5470.7% | 867.2% |
| FY2020 | $10.2M | -$51.0M | -$1.12 | -$39.3M | -506.8% | 1263.4% |
| FY2019 | — | -$57.9M | -$1.34 | -$52.1M | — | 4896.4% |
| FY2018 | — | -$48.3M | — | -$43.5M | — | -29.7% |
| FY2017 | — | -$33.3M | — | -$30.1M | — | -42.9% |
| FY2016 | $18.5K | -$31.8M | — | -$30.4M | -172505.3% | -90.1% |
Source: annual 10-K filings on SEC EDGAR. Figures in USD.
Executive summary
CRESCENT BIOPHARMA, INC. is a consistent compounder, expanding top-line revenue at 103.0% annually over the past decade.
CRESCENT BIOPHARMA, INC. returns on capital have been average, hovering around 10.2% ROIC over the decade.
CRESCENT BIOPHARMA, INC. capital allocation metrics are N/A for the decade; share count and net debt history are incomplete.
Benjamin Graham lens
Under Benjamin Graham's formula using SEC EDGAR fundamentals, CRESCENT BIOPHARMA, INC. is modeled at 15.0% normalized earnings growth with a 5.1% bond-yield adjustment. The resulting Graham intrinsic value estimate is $-79.30 per share.